Entrectinib demonstrates prolonged efficacy in an adult case of radiation-refractory NTRK fusion glioblastoma

Abstract

The National Comprehensive Cancer Network (NCCN) guidelines for glioma in 2021 outline larotrectinib and entrectinib as appropriate therapies for disease harboring neurotrophic tyrosine kinase (NTRK) gene fusions.1 While some efficacy has been reported with larotrectinib in case reports and early clinical studies, to date, there have been no published reports of the successful use of entrectinib in adult gliomas, including glioblastoma (GBM). Here, we outline the first known case of successful use of this agent in the recurrent setting for an adult patient with an NTRK fusion (BCR-NTRK2) GBM.